Compass Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Compass reported Q2 2026 net loss of $25.2M ($0.13/share) vs. $19.9M ($0.14/share) in Q2 2025; cash and marketable securities of $180M (down $29M from Dec 2025 year-end) with runway into 2028. Lead candidate tovecimig (DLL4×VEGF-A) improved to 18.0% ORR (20/111 patients) in Phase 2/3 biliary tract cancer study (p=0.0228 vs. paclitaxel 5.3%); FDA feedback expected Q3 2026 prior to potential BLA filing. Pipeline includes CTX-8371 (PD-1×PD-L1) cohort expansions in triple-negative breast cancer, Hodgkin lymphoma, and NSCLC; CTX-10726 (PD-1×VEGF-A) Phase 1 initiated with data expected Q4; CTX-471 Phase 2 to start Q3.
Why this rating
Tovecimig modest efficacy (18% ORR) in rare indication; FDA feedback and BLA path are material catalysts. $180M runway to 2028 adequate for pipeline. Increased burn ($32M H1 2026) and elevated operating expenses offset by clinical progress. Event significant but not transformational for $277M market-cap company.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.